574 related articles for article (PubMed ID: 27576132)
1. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
2. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.
Ramani VC; Purushothaman A; Stewart MD; Thompson CA; Vlodavsky I; Au JL; Sanderson RD
FEBS J; 2013 May; 280(10):2294-306. PubMed ID: 23374281
[TBL] [Abstract][Full Text] [Related]
3. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.
Barash U; Cohen-Kaplan V; Dowek I; Sanderson RD; Ilan N; Vlodavsky I
FEBS J; 2010 Oct; 277(19):3890-903. PubMed ID: 20840586
[TBL] [Abstract][Full Text] [Related]
4. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.
Sanderson RD; Elkin M; Rapraeger AC; Ilan N; Vlodavsky I
FEBS J; 2017 Jan; 284(1):42-55. PubMed ID: 27758044
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the discovery of heparanase inhibitors as anti-cancer agents.
Jia L; Ma S
Eur J Med Chem; 2016 Oct; 121():209-220. PubMed ID: 27240275
[TBL] [Abstract][Full Text] [Related]
6. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
7. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway.
Yu S; Lv H; Zhang H; Jiang Y; Hong Y; Xia R; Zhang Q; Ju W; Jiang L; Ou G; Zhang J; Wang S; Zhang J
Biochem Biophys Res Commun; 2017 Apr; 485(2):432-439. PubMed ID: 28209511
[TBL] [Abstract][Full Text] [Related]
8. The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas.
Cassinelli G; Zaffaroni N; Lanzi C
Cancer Lett; 2016 Nov; 382(2):245-254. PubMed ID: 27666777
[TBL] [Abstract][Full Text] [Related]
9. Development of heparanase inhibitors for anti-cancer therapy.
Miao HQ; Liu H; Navarro E; Kussie P; Zhu Z
Curr Med Chem; 2006; 13(18):2101-11. PubMed ID: 16918340
[TBL] [Abstract][Full Text] [Related]
10. The Good and Bad Sides of Heparanase-1 and Heparanase-2.
Pinhal MAS; Melo CM; Nader HB
Adv Exp Med Biol; 2020; 1221():821-845. PubMed ID: 32274740
[TBL] [Abstract][Full Text] [Related]
11. Heparanase and cancer progression: New directions, new promises.
Arvatz G; Weissmann M; Ilan N; Vlodavsky I
Hum Vaccin Immunother; 2016 Sep; 12(9):2253-6. PubMed ID: 27054564
[TBL] [Abstract][Full Text] [Related]
12. Targeting heparanase for cancer therapy at the tumor-matrix interface.
Sanderson RD; Iozzo RV
Matrix Biol; 2012 Jun; 31(5):283-4. PubMed ID: 22655968
[No Abstract] [Full Text] [Related]
13. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.
Joyce JA; Freeman C; Meyer-Morse N; Parish CR; Hanahan D
Oncogene; 2005 Jun; 24(25):4037-51. PubMed ID: 15806157
[TBL] [Abstract][Full Text] [Related]
14. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
15. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
[TBL] [Abstract][Full Text] [Related]
16. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.
Purushothaman A; Uyama T; Kobayashi F; Yamada S; Sugahara K; Rapraeger AC; Sanderson RD
Blood; 2010 Mar; 115(12):2449-57. PubMed ID: 20097882
[TBL] [Abstract][Full Text] [Related]
17. Heparanase multiple effects in cancer.
Nadir Y; Brenner B
Thromb Res; 2014 May; 133 Suppl 2():S90-4. PubMed ID: 24862152
[TBL] [Abstract][Full Text] [Related]
18. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase.
Wilson JC; Laloo AE; Singh S; Ferro V
Biochem Biophys Res Commun; 2014 Jan; 443(1):185-8. PubMed ID: 24291708
[TBL] [Abstract][Full Text] [Related]
19. Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity.
Baburajeev CP; Mohan CD; Rangappa S; Mason DJ; Fuchs JE; Bender A; Barash U; Vlodavsky I; Basappa ; Rangappa KS
BMC Cancer; 2017 Mar; 17(1):235. PubMed ID: 28359266
[TBL] [Abstract][Full Text] [Related]
20. Heparanase involvement in physiology and disease.
Nasser NJ
Cell Mol Life Sci; 2008 Jun; 65(11):1706-15. PubMed ID: 18425416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
